太龙药业：关于联合关联方共同受让产业基金份额、变更基金管理人的进展公告

Core Points - Tai Long Pharmaceutical announced a board meeting on December 26, 2023, to approve the transfer of fund shares and change of fund manager [2] - The company’s wholly-owned subsidiary, Hangzhou Tai Long Jin Tang Enterprise Management Co., Ltd., will acquire 0.67% of the ordinary partnership shares of the Beijing-Hong Kong Advanced Manufacturing Industry Equity Investment Fund for RMB 2.1979 million [2] - The subsidiary will also acquire 82.33% of the limited partnership shares of Zhengzhou Longhua Pharmaceutical Industry Fund for RMB 190.9653 million, increasing its total holding to 55% [2] - The fund manager will be changed to Tibet Jinyuan Investment Management Co., Ltd., with the change already filed with the Asset Management Association of China [2]